Novo Nordisk’s ousting of longtime CEO Lars Fruergaard Jørgensen bemused analysts, with many questioning the future of the Wegovy obesity drug maker.
Source link
Trending
- Is the UK going to see tax hikes in autumn? Economists say it’s likely
- Energy CEOs cautious on forecasting oil prices
- Taiwan blacklists China’s Huawei and SMIC, aligning more with U.S. policy
- Cebu Pacific COO on the carrier’s fuel hedge and growth outlook
- Trump administration weighs adding 36 countries to travel ban: Reuters
- Santos shares surge over 15% after $18.7 bil takeover bid
- China retail sales, industrial output, fixed asset investment for May
- Israel’s conflict with Iran sends tremors through markets
Novo Nordisk's future in doubt after Wegovy maker's 'surprise' CEO ouster
